Sarepta Therapeutics
Elevidys — AAV rh74 micro-dystrophin.
- Country
- United States
- Ticker
- SRPT
FDA approved
Coverage
| CN | EU | US | |
|---|---|---|---|
| regenerative-personalized | ✓ | ✓ | ✓ |
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| In-vivo gene therapy: AAV and lentiviral vectors | therapeutics-platforms | Medium | → |
| Nucleic acid therapeutics (oligonucleotides) | therapeutics-platforms | Low | → |
| Personalized & regenerative medicine | regenerative-personalized | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.